Fax (011) 34-91-191-7862
Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma†
Version of Record online: 20 FEB 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 9, pages 1892–1898, 1 May 2009
How to Cite
Garcia-Marco, J. A., Panizo, C., Garcia, E. S., Deben, G., Alvarez-Larran, A., Barca, E. G., Sancho, J. M., Penarrubia, M. J., Garcia-Cerecedo, T. and García-Vela, J. A. (2009), Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer, 115: 1892–1898. doi: 10.1002/cncr.24204
The following physicians kindly contributed patients to this study: Belen Navarro Matilla (Hospital Universitario Puerta de Hierro, Madrid, Spain); Guillermo Pérez (Hospital Severo Ochoa, Leganés, Spain); Alberto Cantalapiedra (Hospital Río Hortega, Valladolid, Spain); Almudena Martín (Hospital La Mancha Centro, Alcazar de San Juan, Spain); Enric Grau (Hospital Lluis Alcanyis, Alicante, Spain); Esperanza Romero (Hospital Arquitecto Marcide, Ferrol, La Spain); Francisco Javier Capote (Hospital Puerta del Mar, Cádiz, Spain); Joaquín Casal Rubio (Hospital Meixoeiro, Vigo, Spain); Joaquín Díaz, Rafael Martínez (Clínico Universitario San Carlos, Madrid, Spain); Jose Antonio Márquez (Hospital Basurto, Bilbao, Spain); Jose Javier Sánchez Blanco (Hospital Morales Meseguer, Murcia, Spain); Jose María Guinea (Hospital Txagorritxu, Vitoria-Gasteiz, Spain); Lucía Villalón (Fundación Hospital, Alcorcón, Spain); Miguel Nogué (Hospital General de Vic, Vic, Spain); Pilar Galán Álvarez (Hospital Virgen del Toro, Mahón, Spain); Yolanda Martín (Hospital Príncipe de Asturias, Alcalá de Henares, Spain); Fernando Solano (Hospital Nuestra Señora del Prado, Toledo, Spain); Gonzalo López, Elena Amutio (Hospital de Cruces, Bilbao, Spain); Reyes Arranz (Hospital Princesa, Madrid, Spain); Jose Sarra, Ana Carla Oliveira Ramos (Hospital Duran i Reynals, Institut Català d'Oncologia, Hospitalet, Barcelona, Spain); and Luis Palomera (Hospital Clínico Lozano Blesa, Zaragoza, Spain).
- Issue online: 20 APR 2009
- Version of Record online: 20 FEB 2009
- Manuscript Accepted: 24 OCT 2008
- Manuscript Revised: 20 OCT 2008
- Manuscript Received: 2 JUL 2008
- meningeal neoplasms;
Standard intrathecal chemotherapy for lymphomatous meningitis (LM) is limited by the short cerebrospinal half-lives of the agents used, necessitating frequent administration. Liposomal cytarabine (DepoCyte) has an extended half-life that permits administration at 2- to 4-weekly intervals.
Patients with LM who underwent treatment with liposomal cytarabine at treatment centers in Spain between 2004 and 2007 were identified. Data on demographics, treatment, and outcomes were extracted from medical notes and entered, retrospectively, into a database for analysis.
Data on 55 patients with lymphoma (mainly stage IV) and LM were entered into the database. Most patients (n = 36) had diffuse large B-cell lymphoma. The median number of cycles of liposomal cytarabine received was 4 (range, 1-10), and the median follow-up period was 124 days. Complete and partial neurologic responses were achieved in 27 and 12 patients, respectively (overall response rate, 72%), all of whom also showed a cytological response, except for 5 with initially negative cytology. Median time to neurologic progression among responders was 105.5 days. Liposomal cytarabine was generally well tolerated; headache was the most commonly reported adverse effect (n = 17).
Liposomal cytarabine is effective and well tolerated in the treatment of LM, and should be considered as an agent of choice for the treatment of this complication. Cancer 2009. © 2009 American Cancer Society.